TGFB1 and systemic sclerosis: Together, the discoveries of these abnormal SSc fibroblast phenotypes motivated multiple efforts to identify modifiers of fibroblast biology as an anti-fibrotic strategy, including targeting the TGFβ pathway, the extracellular matrix organization and myofibroblast contractility26.